A 2-part, randomized, double-blind, placebo-controlled, multiple-rising dose study to evaluate the safety, tolerability, and pharmacokinetics of MK3281 in healthy male subjects and safety, tolerability, pharmacokinetics and pharmacodynamics of MK3281 in hepatitis C infected male patients.
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs MK 3281 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 18 Oct 2016 Status changed from discontinued to completed.
- 05 Jan 2012 Planned end date changed from 1 Dec 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 12 Feb 2010 Actual patient number (60) added as reported by ClinicalTrials.gov.